Clinical Analysis of Acute Lung Injury in 26 Cases of Diffuse Large B-Cell Lymphoma Treated with Rituximab Chemotherapy.
10.19746/j.cnki.issn.1009-2137.2020.06.021
- Author:
Dong ZHENG
1
;
Fei DONG
1
;
Meng PANG
1
;
Wei ZHAO
1
;
Lei TIAN
1
;
Jing WANG
1
;
Xiao-Yan KE
2
Author Information
1. Department of Hematology, The Third Hospital of Peking University, Beijing 100191, China.
2. Department of Hematology, The Third Hospital of Peking University, Beijing 100191, China E-mail: xiaoyank@yahoo.com.
- Publication Type:Journal Article
- MeSH:
Acute Lung Injury;
Antineoplastic Combined Chemotherapy Protocols;
Cyclophosphamide/therapeutic use*;
Doxorubicin/therapeutic use*;
Humans;
Lymphoma, Large B-Cell, Diffuse/drug therapy*;
Prognosis;
Rituximab/therapeutic use*;
Treatment Outcome;
Vincristine/therapeutic use*
- From:
Journal of Experimental Hematology
2020;28(6):1919-1922
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To summarize and analyze the clinical characteristics, treatment and prognosis of acute lung injury in patients with diffuse large B-cell lymphoma (DLBCL) after chemotherapy with rituximab chemotherapy, so as to improve the understanding of the disease and guide the clinical treatment.
METHODS:Twenty-Six patients with DLBCL were treated with rituximab chemotherapy and developed to acute lung injury in Third Hospital of Peking University from January 2013 to September 2018 were selected. The clinical features, imaging findings, chemotherapy course, therapeutic effect and prognosis were analyzed.
RESULTS:The main clinical symptoms of patients were fever, cough and chest tightness, among which 12 patients showed hypoxia and 3 patients showed respiratory failure type I. The mainly manifested chest CT was diffusive glass grinding in both lungs, and some patients were complicated with a small amount of pleural effusion. The onset chemotherapy time was mainly distributed in 2 to 4 courses, the time between the onset of symptoms and the infusion of rituximab was 8 to 49 days. 25 patients shows no obvious limitation in daily life after effective treatment, and 1 patient died of ineffective treatment.
CONCLUSION:There are no typical clinical symptoms in the early stage of acute lung injury after rituximab chemotherapy in DLBCL. Early detection and early hormone therapy are very important to achieve good therapeutic effect.
